Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

Financial Performance - Fortress Biotech reported a quarterly loss of $0.48 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.44, but an improvement from a loss of $1.03 per share a year ago [1] - The company posted revenues of $13.14 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 27.56%, compared to revenues of $13.03 million in the same quarter last year [2] - Over the last four quarters, Fortress Biotech has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance and Outlook - Fortress Biotech shares have declined approximately 18% since the beginning of the year, while the S&P 500 has gained 0.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.43 on revenues of $14.4 million, and for the current fiscal year, it is -$1.51 on revenues of $101.55 million [7] - The estimate revisions trend for Fortress Biotech is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Fortress Biotech belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]